Osteoarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report

Published: April 29, 2022 Report Code: GMDGDHC22137IDB-ST

Select Item

Osteoarthritis Pipeline Market Overview

Osteoarthritis pipeline market research report provides comprehensive information on the therapeutics under development for Osteoarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects.

Key Targets in the Osteoarthritis Pipeline Market

The key targets in the Osteoarthritis pipeline market are Prostaglandin G/H Synthase 2, Prostaglandin G/H Synthase 1, Interleukin 1 Receptor, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5, Collagenase 3, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 4, and Angiopoietin Related Protein 3. Prostaglandin G/H Synthase 2 has the highest number of pipeline products.

Osteoarthritis Pipeline Market, by Targets

Osteoarthritis Pipeline Market, by Targets

For more target insights, download a free report sample

Key MoA in the Osteoarthritis Pipeline Market

The key MoA in the Osteoarthritis pipeline market are Prostaglandin G/H Synthase 2 Inhibitor, Prostaglandin G/H Synthase 1 Inhibitor, Interleukin 1 Receptor Antagonist, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 Inhibitor, Collagenase 3 Inhibitor, and A Disintegrin And Metalloproteinase With Thrombospondin Motifs 4 Inhibitor. Prostaglandin G/H Synthase 2 Inhibitor has the highest number of pipeline products.

Osteoarthritis Pipeline Market, by MoA

Osteoarthritis Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Osteoarthritis Pipeline Market

The key RoA in the Osteoarthritis pipeline market are intraarticular, oral, parenteral, intravenous, subcutaneous, intramuscular, and topical. Intraarticular has the highest number of pipeline products.

Osteoarthritis Pipeline Market, by RoA

Osteoarthritis Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Osteoarthritis Pipeline Market

The key molecule types in the Osteoarthritis pipeline market are small molecule, cell therapy, biologic, fusion protein, gene therapy, and monoclonal antibody. Small molecule has the highest number of pipeline products.

Osteoarthritis Pipeline Market, by Molecule Types

Osteoarthritis Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Osteoarthritis Pipeline Market

The key companies in the Osteoarthritis pipeline market are Novartis AG, LG Chem Ltd, Link Health Group, MediPost Co Ltd, biogen Pharma SpA, Achelios Therapeutics Inc, Atlanthera, and CarthroniX Inc. Novartis AG has the highest number of pipeline products.

Osteoarthritis Pipeline Market, by Companies

Osteoarthritis Pipeline Market, by Companies

To know about more companies, download a free report sample

Market report overview

Key targets Prostaglandin G/H Synthase 2, Prostaglandin G/H Synthase 1, Interleukin 1 Receptor, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5, Collagenase 3, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 4, and Angiopoietin Related Protein 3
Key MoA Prostaglandin G/H Synthase 2 Inhibitor, Prostaglandin G/H Synthase 1 Inhibitor, Interleukin 1 Receptor Antagonist, A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 Inhibitor, Collagenase 3 Inhibitor, and A Disintegrin And Metalloproteinase With Thrombospondin Motifs 4 Inhibitor
Key RoA Intraarticular, Oral, Parenteral, Intravenous, Subcutaneous, Intramuscular, and Topical
Key Molecule Types Small Molecule, Cell Therapy, Biologic, Fusion Protein, Gene Therapy, and Monoclonal Antibody
Key Companies Novartis AG, LG Chem Ltd, Link Health Group, MediPost Co Ltd, biogen Pharma SpA, Achelios Therapeutics Inc, Atlanthera, and CarthroniX Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Musculoskeletal Disorders).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

20MED Therapeutics BV
4P-Pharma SAS
Abiogen Pharma SpA
Achelios Therapeutics Inc
Aclaris Therapeutics Inc
Adare Pharma Solutions
AfaSci Inc
Ageless Biotech Inc
Akaal Pharma Pty Ltd
Akan Biosciences LLC
AKL Research and Development Ltd
Algomedix Inc
Amgen Inc
Amplicore Inc
Amzell BV
Aprogen Inc
AskAt Inc
Asta Pharmaceuticals Co Ltd
Atlanthera
Aurealis Pharma AG
Axsome Therapeutics Inc
Bioiberica SAU
BioIntegrate Inc
BioNet Pharma GmbH
Bioorg3.14 LLC
Biosplice Therapeutics Inc
BioStem Technologies Inc
Bioventus Inc
BRIM Biotechnology Inc
Buzzz Pharmaceuticals Ltd
Caliway Biopharmaceutics Co Ltd
CAR-T (Shanghai) Biotechnology Co Ltd
Cartesian Therapeutics Inc
CarthroniX Inc
Cartilagen Inc
Causeway Therapeutics Ltd
Cellatoz Therapeutics Inc
Cellics Therapeutics Inc
CELLnLIFE Inc
Cells for Cells SA
CellTex Therapeutics Corp
Cellular Biomedicine Group Inc
Chondrogenix Ltd
Cmxtwenty
Cocoon Biotech, Inc.
Corestem Inc
CrystalGenomics Inc
Cynata Therapeutics Ltd
Cytonics Corp
Cytopeutics Pte Ltd
Daewoong Pharmaceutical Co Ltd
Dianomi Therapeutics Inc
DNX Biopharmaceuticals Inc
Dongkook Pharmaceutical Co Ltd
Eli Lilly and Co
Ensol Biosciences Inc
Enveric Biosciences Inc
Epione Therapeutics BV
Eternity Bioscience Inc
Evgen Pharma Plc
Exostemtech Co Ltd
Flexion Therapeutics Inc
Genascence Corp
Genequine Biotherapeutics GmbH
General Regeneratives Shanghai Ltd
General Therapeutics Inc
GlaxoSmithKline Plc
GPN Therapeutics Inc
Guangzhou Saliai Stemcell Science and Technology Co Ltd
Gwoxi Stem Cell Applied Technology Co Ltd
Haplnscience Inc
Hisamitsu Pharmaceutical Co Inc
Histogen Inc
Hope Biosciences LLC
Huaxia Source Cell Engineering Group Co Ltd
iCELL Biotechnology Co Ltd
ICM Co Ltd
Immetas Therapeutics Inc
ImmuneCyte Inc
ImmunoForge Co Ltd
Inception Therapeutics Inc
International Stem Cell Corp
Johnson & Johnson
Juniper Biologics Pte Ltd
Juvena Therapeutics Inc
Kaken Pharmaceutical Co Ltd
Kangstem Biotech Co Ltd
Kolon TissueGene Inc
Kukje Pharmaceutical Industry Co Ltd
Levolta Pharmaceuticals Inc
LG Chem Ltd
Likarda LLC
Link Biologics Ltd
Link Health Group
Lubris Biopharma
Luye Pharma Group Ltd
Magellan Biologicals Pty Ltd
MDimune Inc
Mecox Cure Med Co Ltd
Medicrinia Co Ltd
MediPost Co Ltd
Medivir AB
MeiraGTx Holdings Plc
Meluha Life Sciences Sdn Bhd
Merck KGaA
Meridigen Biotech Co Ltd
Mesoblast Ltd
MetrioPharm AG
MiMedx Group Inc
Mor Research Applications Ltd
Nanode Therapeutics Inc
NeuroBo Pharmaceuticals Inc
New York R&D Center for Translational Medicine and Therapeutics Inc
Nexbiome Therapeutics
Nordic Bioscience AS
Novartis AG
Novo Nordisk AS
Orbsen Therapeutics Ltd
Organicell Regenerative Medicine Inc
Organogenesis Holdings Inc
OrthoTrophix Inc
Oxacell AG
Paradigm Biopharmaceuticals Ltd
Paras Biopharmaceuticals Finland Oy
Parnia Stem Cell Knowledge-Based Co
Peptinov SAS
Personalized Stem Cells Inc
PersonGen BioTherapeutics (Suzhou) Co Ltd
Pfizer Inc
PhytoHealth Corp
Plakous Therapeutics Inc
PlateletBio
PMG PHARM Co Ltd
PrimeGen Global Inc
PrimRNA Inc
Progenitor Therapeutics Ltd
ProteoThera Inc
Regeneus Ltd
Regenosine Inc
Regulaxis SAS
Remedium Bio Inc
ReqMed Co Ltd
Ribomic Inc
Rottapharm Biotech Srl
Runjia (Suzhou) Pharmaceutical Technology Co Ltd
Sclnow Biotechnology Co Ltd
Seikagaku Corp
Serene LLC
Shandong Boan Biotechnology Co Ltd
Shionogi & Co Ltd
Simcere Pharmaceutical Group Ltd
SL Bigen Co Ltd
Steminent Biotherapeutics Inc
Stempeutics Research Pvt Ltd
Synartro AB
Synerkine Pharma BV
Synokem Pharmaceuticals Ltd
Taiwan Bio Therapeutics Co Ltd
Techfields Pharma Co Ltd
TheraBioPharma Inc
Traverse Biosciences Inc
Tremeau Pharmaceuticals Inc
Trialspark Inc
Turn Biotechnologies Inc
Unicocell Biomed Co Ltd
Vitro Diagnostics Inc
WEX Pharmaceuticals Inc
WNT Scientific LLC
Xalud Therapeutics Inc
Xintela AB
Yooyoung Pharm Co Ltd
Zhejiang Yatai Pharmaceutical Co Ltd
Zimmer Biomet Holdings Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Osteoarthritis – Overview

Osteoarthritis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Osteoarthritis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Osteoarthritis – Companies Involved in Therapeutics Development

Osteoarthritis – Drug Profiles

Osteoarthritis – Dormant Projects

Osteoarthritis – Discontinued Products

Osteoarthritis – Product Development Milestones

Featured News & Press Releases

Apr 13, 2022: FDA grants Fast Track Designation for Paradigm Biopharmaceuticals phase III osteoarthritis program

Apr 08, 2022: TPX-100: OrthoTrophix presents new data suggesting joint bone shape as a possible surrogate marker for virtual joint replacement in knee osteoarthritis

Mar 17, 2022: Paradigm Biopharmaceuticals initiates a phase 3 clinical trial in knee osteoarthritis across the U.S

Mar 17, 2022: Paradigm has received regulatory and ethics approvals for the PARA_OA_002 clinical trial in the UK.

Mar 14, 2022: Medipost begins administration of knee osteoarthritis drug in P2 trial

Mar 03, 2022: 4P-Pharma and QuantHealth join forces to conduct AI-based in-Silico clinical trial simulations

Feb 17, 2022: Synartro granted European patent

Feb 08, 2022: Enveric Biosciences announces successful synthesis and filing of provisional patent for EV-104a – Cannabinoid + Celecoxib Conjugate

Jan 13, 2022: First subjects randomised dosed in PARA_0A_002 phase 3 study in Australia

Jan 12, 2022: Paradigm presentation at the 40th Annual J.P. Morgan Healthcare Conference

Dec 28, 2021: Kolon TissueGene resumes TG-C phase III studies in the U.S.

Dec 13, 2021: FDA approves XBiotech’s IND in rheumatology

Dec 03, 2021: Kolon TissueGene to expand indications for TG-C

Nov 01, 2021: Two new studies demonstrate in vitro bioactivity potential of micronized dehydrated human amnion chorion membrane (mdHACM) to prevent pathological processes underlying osteoarthritis (OA) and tendinopathy

Sep 21, 2021: TPX-100: OrthoTrophix published a new research article demonstrating disease modification in knee osteoarthritis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

Osteoarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Musculoskeletal Disorders reports
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Pharmaceuticals
New
Net Present Value Model: Sarepta Therapeutics Inc's Patidistrogene bexoparvovec
$500 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Osteoarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Osteoarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more